Focus: Cumberland Pharmaceuticals is a specialty pharma company headquartered in Nashville, TN, focused on small molecule drugs in neurology and acute care settings. The company operates a focused portfolio of marketed drugs with significant pipeline activity across multiple therapeutic areas.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow Cumberland Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Company's cash cow with 90% revenue concentration; approaching generic competition creates existential cash flow risk.
Help build intelligence for Cumberland Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Cumberland Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Secondary revenue generator with confirmed LOE date; $782K annual revenue at risk by 2027.
Niche acute care product with patent protection until 2032; limited market but stable for next 7+ years.
IV formulation in acute/post-operative settings; patent-protected until 2032, mitigating near-term cliff.
4 discontinued, 1 duplicate formulations not shown
No open positions listed yet.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub
Supply chain instability (Conivaptan shortage) and product LOE timeline suggest operational strain; layoff risk rises materially if SANCUSO experiences unexpected revenue decline.